Full text is available at the source.
Abstract
Access to GLP-1 medicines for type 2 diabetes is often limited by subsidies in high-income countries.
- GLP-1 medicines offer significant heart and kidney health benefits for individuals with type 2 diabetes.
- These medications are increasingly prescribed for weight loss purposes.
- Usage of GLP-1 medicines outside subsidized access typically occurs through private prescriptions.
- There is strong consumer demand for GLP-1 medicines, yet the extent of private access is not well understood.
Simplified